Volume 27, Issue 4 (Iran South Med J 2025)
Iran South Med J 2025, 27(4): 258-266 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Navabi P, Bitarf S, Rastegar M H, Ahmadi-Rad Z, Farhadikia F, Salehi Kahyesh R. Factors Affecting the Prevalence and Survival of Patients with Primary and Metastatic Brain Tumors. Iran South Med J 2025; 27 (4) :258-266
URL: http://ismj.bpums.ac.ir/article-1-2091-en.html
URL: http://ismj.bpums.ac.ir/article-1-2091-en.html
Parisa Navabi1 
, Saeed Bitarf2 , Mohammad Hosein Rastegar2 , Zainab Ahmadi-Rad2 , Farhad Farhadikia3 , Roya Salehi Kahyesh *4
, Saeed Bitarf2 , Mohammad Hosein Rastegar2 , Zainab Ahmadi-Rad2 , Farhad Farhadikia3 , Roya Salehi Kahyesh *4
1- Persian Gulf Physiology Research Center, Institute of Basic Medical Sciences, Ahvaz Jundishapur Uni-versity of Medical Sciences, Ahvaz, Iran
2- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3- Department of General Medicine, School of Medicine, Izmir University of Ekonomics, Izmir, Turkey
4- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ,royaarta@yahoo.com
2- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3- Department of General Medicine, School of Medicine, Izmir University of Ekonomics, Izmir, Turkey
4- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ,
Abstract: (281 Views)
Background: Brain metastases are a major cause of mortality in patients, with an estimated 10-20% of cancers metastasizing to the brain.
Materials and Methods: This study examined the records of patients with brain tumors (both primary and metastatic) who were hospitalized at Baghaei 2 Hospital in Ahvaz from 2017 to 2022. The impact of factors such as gender, age at diagnosis, tumor site, disease stage, and type of treatment on 5-year survival was assessed using the Cox proportional hazards model.
Results: This research investigated 302 patients, including 172 with primary tumors and 130 with metastatic tumors. The mean age of the patients with primary brain tumors was 23.06 years, while for patients with metastasis, it was 53.46 years. The most common primary sites of the metastatic tumors were the lung and breast. The results demonstrated a significant relationship between tumor type (primary or metastatic) and survival, indicating that survival was higher in patients with primary tumors. Additionally, neither the type of treatment nor tumor type significantly affected patient
survival. There was no significant relationship between gender and type of brain tumor.
Conclusion: This study shows that the type of brain tumor (primary or metastatic), the initial site of involvement in the metastatic tumor, and the type of treatment did not affect the survival of patients with brain metastases. The threat of a tumor depends on a combination of factors, and patients who can tolerate surgery may have a better chance of survival.
Materials and Methods: This study examined the records of patients with brain tumors (both primary and metastatic) who were hospitalized at Baghaei 2 Hospital in Ahvaz from 2017 to 2022. The impact of factors such as gender, age at diagnosis, tumor site, disease stage, and type of treatment on 5-year survival was assessed using the Cox proportional hazards model.
Results: This research investigated 302 patients, including 172 with primary tumors and 130 with metastatic tumors. The mean age of the patients with primary brain tumors was 23.06 years, while for patients with metastasis, it was 53.46 years. The most common primary sites of the metastatic tumors were the lung and breast. The results demonstrated a significant relationship between tumor type (primary or metastatic) and survival, indicating that survival was higher in patients with primary tumors. Additionally, neither the type of treatment nor tumor type significantly affected patient
survival. There was no significant relationship between gender and type of brain tumor.
Conclusion: This study shows that the type of brain tumor (primary or metastatic), the initial site of involvement in the metastatic tumor, and the type of treatment did not affect the survival of patients with brain metastases. The threat of a tumor depends on a combination of factors, and patients who can tolerate surgery may have a better chance of survival.
Type of Study: Original |
Subject:
Blood and cancer
Received: 2024/12/21 | Accepted: 2025/02/9 | Published: 2025/03/10
Received: 2024/12/21 | Accepted: 2025/02/9 | Published: 2025/03/10
References
1. Lin YY, Wang Y- C, Yeh D- W, et al. Gene Expression Profile in Primary Tumor Is Associated with Brain-Tropism of Metastasis from Lung Adenocarcinoma. Int J Mol Sci 2021; 22(24): 13374. [DOI]
2. Pourkamalzadeh.M, Abtahi foroshani.SM. In -vitro Apoptotic Effects of Deferoxamine on the Glioblastoma Cell Line, Iran South Med J 2019; 22(5): 264-277. [DOI]
3. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005- 2009. Neuro Oncol 2012; 14(5): v1-49. [DOI]
4. Liu Q, Tong X, Wang J. Management of brain metastases: history and the present. Chin Neurosurg J 2019; 5: 1. [DOI]
5. Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int 2013; 4(Suppl 4): S192-202. [DOI]
6. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro Oncol 2017; 19(11): 1511–1521. [DOI]
7. Hall WA, Djalilian HR, Nussbaum ES, et al. Long-term survival with metastatic cancer to the brain. Med Oncol 2000; 17(4): 279-86. [DOI]
8. Shih DJH, Nayyar N, Bihun I, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat. Genet 2020; 52(4): 371–377.
9. Wang H; Ou Q; Li D, et al. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer 2019; 125(20), 3535–3544. [DOI]
10. Porouhan P, Yousefabadi R, Abbaspour A, et al. Survival of Patients with Metastatic Brain Tumors in Sabzevar, 2016-2021. Journal of Sabzevar University of Medical Sciences 2023; 30(4): 442-52. [DOI]
11. Doğan A, Durmaz MO, Gezgin İ, et al. Surgical Management and Postoperative Outcome in patients with Brain Metastases: Our Surgical Experience. Journal of Nervous System Surgery 2022; 8(2): 51-9. [Article]
12. Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010; 12(6): 520-7. [DOI]
13. Yri O, Astrup G, Karlsson A, et al. 282MO Brain metastases: Real-life treatment patterns, survival, and patient-reported outcomes–Results from a populationbased, prospective study in 914 patients. Annals of Oncology 2022; 33: S668. [DOI]
14. Díaz-Pernas FJ, Martínez-Zarzuela M, AntónRodríguez M, et al. A Deep Learning Approach for Brain Tumor Classification and Segmentation Using a Multiscale Convolutional Neural Network. Healthcare (Basel) 2021; 9(2): 153. [DOI]
15. Nikolov V, Radisavljević M, Jelenković B, et al. Current approaches to the treatment of metastatic brain tumors. Vojnosanit Pregl 2023; 80(6): 487–492. [DOI]
16. Sperduto PW, Yang TJ, Beal K, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (LungmolGPA). JAMA Oncol 2017; 3(6): 827-831. [DOI]
17. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70(2): 510-4. [DOI]
18. Rotta JM, Rodrigues DB, Diniz JM , et al. Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site. Rev Assoc Med Bras (1992) 2018; 64(8): 717-722. [DOI]
19. Achey RL, Gittleman H, Schroer J, et al. Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States. Neuro Oncol 2019; 21(3): 380-391. [DOI]
20. D'Andrea G, Angelini A, Romano A, et al. Intraoperative DTI and brain mapping for surgery of neoplasm of the motor cortex and the corticospinal tract: our protocol and series in BrainSUITE. Neurosurg Rev 2012; 35(3): 401-12. [DOI]
21. De la Garza-Ramos R, Kerezoudis P, Tamargo RJ, et al. Surgical complications following malignant brain tumor surgery: An analysis of 2002-2011 data. Clin Neurol Neurosurg 2016; 140: 6-10. [DOI]
22. Fabi A, Felici A, Metro G, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res 2011; 30(1): 10. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
